Join the Retinopathy group to help and get support from people like you.
Retinopathy News
Study Identifies Factors Associated With Hydroxychloroquine Retinopathy
MONDAY, May 13, 2024 – Factors associated with an increased risk for hydroxychloroquine retinopathy have been identified and include female sex, older age, and chronic kidney disease stage 3 or...
AI Shows Good Clinical Knowledge, Reasoning for Eye Issues
FRIDAY, April 26, 2024 – Large language models (LLMs) are approaching expert-level knowledge and reasoning skills in ophthalmology, according to a study published online April 17 in PLOS Digital...
American Academy of Ophthalmology, Nov. 3-5
The annual meeting of the American Academy of Ophthalmology was held from Nov. 3 to 5 in San Francisco and attracted participants from around the world, including ophthalmologists, optometrists,...
AAO: Research Highlights Vision Issues Seen in Pediatric Sickle Cell Disease
THURSDAY, Nov. 9, 2023 – For pediatric patients with sickle cell disease (SCD), ophthalmologic complications include nonproliferative retinopathy (NPR) and proliferative retinopathy (PR), which...
Eylea (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
ROP is a leading cause of childhood blindness worldwide Eylea now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) --...
FDA Approves Genentech’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA – April 17, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® ...
Ask a question
To post your own question to this support group, sign in or create an account.